What is SciBac?
SciBac operates at the intersection of synthetic biology and clinical medicine, specializing in the development of live biotherapeutics designed to combat antibiotic-resistant pathogens. By leveraging a proprietary platform, the company engineers hybrid microbial strains that possess specific, targeted traits. These biotherapeutics are engineered to treat complex conditions such as Clostridium difficile infections and chronic Pseudomonas in cystic fibrosis patients, while simultaneously supporting the integrity of the human microbiome. This dual-action approach positions SciBac as a key innovator in the biopharmaceutical sector, moving beyond traditional small-molecule therapies to offer more durable, biologically integrated solutions for patients with limited treatment options.
How much funding has SciBac raised?
SciBac has raised a total of $112K across 1 funding round:
Debt
$112K
Debt (2021): $112K with participation from PPP
Key Investors in SciBac
PPP
Public-Private Partnership
What's next for SciBac?
With this substantial capital, SciBac is well-positioned to accelerate its clinical pipeline and scale its manufacturing capabilities. The strategic focus will likely shift toward advancing its lead candidates through late-stage clinical trials and refining its hybrid strain development process. As the company matures, the emphasis will remain on demonstrating the efficacy of its platform in real-world clinical settings, potentially paving the way for regulatory milestones and commercialization. The firm's ability to maintain its competitive edge in the microbiome space will be contingent upon its continued success in navigating the complex regulatory landscape for live biotherapeutic products and expanding its therapeutic reach into additional high-need indications.
See full SciBac company page
